Top ▲

TEAD (transcriptional enhanced associate domain) transcription factors

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

Overview

Click here for help

« Hide

There are four human genes that encode TEA domain transcription factors, TEAD1-4. The TEAD TFs bind to YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) proteins, which are downstream effectors of Hippo pathway signalling. The Hippo pathway is frequently activated in tumours, and this abberant activity drives proliferation and survival of cancer cells. Disruption of the interaction between TEADs and YAP/TAZ is a current approach for anti-tumour drug development [1].

Targets

3240
Click here for help

TEAD1 (TEA domain transcription factor 1) Show summary »


Target Id 3240
Nomenclature TEA domain transcription factor 1
Common abbreviation TEAD1
Previous and unofficial names TEF-1 | transcriptional enhancer factor 1 | TCF13
Genes TEAD1 (Hs), Tead1 (Mm), Tead1 (Rn)
Ensembl ID ENSG00000187079 (Hs), ENSMUSG00000055320 (Mm), ENSRNOG00000015488 (Rn)
UniProtKB AC P28347 (Hs)
Inhibitors
GNE-7883 (Binding) pIC50 7.4 [1], 7.3 [1]

TEAD2 (TEA domain transcription factor 2) Show summary »

TEAD3 (TEA domain transcription factor 3) Show summary »

TEAD4 (TEA domain transcription factor 4) Show summary »

References

Click here for help

Show »

How to cite this family page

Database page citation:

TEAD (transcriptional enhanced associate domain) transcription factors. Accessed on 28/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1085.

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Buneman OP, Faccenda E, Harding SD, Spedding M, Cidlowski JA, Fabbro D, Davenport AP, Striessnig J, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: Introduction and Other Protein Targets. Br J Pharmacol. 180 Suppl 2:S1-22.